Ryan James, Zoellner York, Gradl Birgit, Palache Bram, Medema Jeroen
Mapi Values, Adelphi Mill, Bollington, Cheshire, UK.
Vaccine. 2006 Nov 17;24(47-48):6812-22. doi: 10.1016/j.vaccine.2006.07.042. Epub 2006 Aug 4.
In 2003, the World Health Assembly (WHA) issued a resolution for prevention and control of influenza pandemics and annual epidemics, which urges the European Union 25 (EU-25) Member States to (1) establish and implement strategies to increase vaccination coverage of all people at high risk, including the elderly and people with underlying disease, with the goal of attaining vaccination coverage of the elderly population of at least 50% by 2006 and 75% by 2010; (2) to assess the disease burden and economic impact of annual influenza epidemics as a basis for framing and implementing influenza prevention policies. This resolution was reinforced by the European Union (EU), where Member States agreed to make additional efforts to improve uptake on their territory in accordance with their own recommendations and to achieve the World Health Organisation (WHO) target of 75% in high risk groups before 2010. It was also noted that the changing demographic profile of the EU population would result in an increasing number of elderly people falling within the current target groups.
To establish the number of people who may be eligible for influenza vaccination in the EU, and estimate the costs and consequences of not vaccinating this population for five EU Member States, France, Germany, Italy, Spain, and the UK.
A mathematical model has previously been developed, in which vaccine distribution data are combined with demographic and health economics data to model the public health consequences of influenza and possible intervention strategies. We have extended that model using specific EU-25 demographic data on populations at risk of influenza during the inter-pandemic period. For each country, the total population and age breakdown was calculated to estimate the percentage of the population that falls under the WHA recommendations. Other target groups for influenza vaccination were identified by analysing estimating the proportion of the population with respiratory or cardiovascular related diseases, diabetes, AIDS or transplantation, as well as health care professionals. Target population size and possible vaccination coverage rates across the EU-25 Member States, along with the potential cost and health consequence impact is estimated.
For the EU-25, it was estimated that up to 49.1% of the population (or 223.4 million people) should be vaccinated against influenza. This ranged from 41.6% in Cyprus to 56.4% in the UK. There were, on average, 174 vaccine doses distributed per 1000 population within the EU-25, which leads to an average vaccination rate of the target population of 35.4% based on current supply constraints. As a consequence, up to 144.4 million people who could be considered "at risk" may not currently be vaccinated. Implementing a 100% vaccination rate programme for all risk groups across the EU-25 would lead to an estimated reduction of number of influenza cases of 7.22 million, 1.96 million reduced PCP visits for influenza treatment, 796,743 less hospital admissions and 68,537 fewer influenza related deaths for all EU-25 countries. The implementation of a 100% vaccination rate programme for all risk groups in France, Germany, Italy, Spain and UK would require an additional 1.52 billion Euro. This would result in estimated savings of 39.45 million Euro of reduced primary care visits and further savings of 1.59 billion Euro in reduced hospitalisations respectively in these countries.
There is a gap between current vaccination coverage and the EU recommendations. The public health consequences of low vaccination coverage include increased morbidity, hospitalisations and mortality associated with influenza-related complications. This model is a powerful tool to: (1) support EU public health officials in implementing recommendations; (2) to visualize the need for increased vaccination rates for better influenza control; (3) the consequences of low vaccine coverage.
2003年,世界卫生大会(WHA)发布了一项关于预防和控制流感大流行及年度流行的决议,敦促欧盟25国(EU - 25)成员国:(1)制定并实施战略,以提高所有高危人群的疫苗接种覆盖率,包括老年人和患有基础疾病的人群,目标是到2006年使老年人群的疫苗接种覆盖率至少达到50%,到2010年达到75%;(2)评估年度流感流行的疾病负担和经济影响,作为制定和实施流感预防政策的依据。欧盟(EU)强化了该决议,各成员国同意根据自身建议做出额外努力,以提高其境内的疫苗接种率,并在2010年前实现世界卫生组织(WHO)设定的高危人群75%的目标。还指出,欧盟人口结构的变化将导致当前目标群体中的老年人数量增加。
确定欧盟可能有资格接种流感疫苗的人数,并估计法国、德国、意大利、西班牙和英国这五个欧盟成员国不对该人群进行疫苗接种的成本和后果。
此前已开发出一个数学模型,其中将疫苗分发数据与人口统计学和卫生经济学数据相结合,以模拟流感的公共卫生后果及可能的干预策略。我们利用欧盟25国在大流行间期流感高危人群的特定人口统计学数据对该模型进行了扩展。对于每个国家,计算总人口和年龄分布,以估计符合世界卫生大会建议的人口百分比。通过分析估计患有呼吸道或心血管相关疾病、糖尿病、艾滋病或接受移植的人群以及医护人员在总人口中的比例,确定了其他流感疫苗接种目标群体。估计了欧盟25国的目标人群规模和可能的疫苗接种覆盖率,以及潜在成本和对健康后果的影响。
对于欧盟25国,估计高达49.1%的人口(即2.234亿人)应接种流感疫苗。这一比例在塞浦路斯为41.6%,在英国为56.4%。在欧盟25国,每1000人口平均分发174剂疫苗,基于当前的供应限制,目标人群的平均接种率为35.4%。因此,目前可能有多达1.444亿被视为“高危”的人未接种疫苗。在欧盟25国对所有风险群体实施100%的疫苗接种率计划,预计将使所有欧盟25国的流感病例数减少722万例,因流感治疗而进行的初级保健门诊减少196万次,住院人数减少796,743例,与流感相关的死亡人数减少68,537例。在法国、德国、意大利、西班牙和英国对所有风险群体实施100%的疫苗接种率计划将需要额外15.2亿欧元。这将分别使这些国家因初级保健门诊减少估计节省3945万欧元,并因住院人数减少进一步节省15.9亿欧元。
当前的疫苗接种覆盖率与欧盟的建议之间存在差距。疫苗接种覆盖率低的公共卫生后果包括与流感相关并发症导致的发病率、住院率和死亡率增加。该模型是一个强大的工具,可用于:(1)支持欧盟公共卫生官员实施建议;(2)直观显示提高疫苗接种率以更好控制流感的必要性;(3)疫苗接种覆盖率低的后果。